BL Pharmtech Statistics
Total Valuation
BL Pharmtech has a market cap or net worth of KRW 16.49 billion. The enterprise value is 21.25 billion.
Market Cap | 16.49B |
Enterprise Value | 21.25B |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
Earnings Date | Mar 21, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
BL Pharmtech has 8.90 million shares outstanding. The number of shares has increased by 0.78% in one year.
Current Share Class | n/a |
Shares Outstanding | 8.90M |
Shares Change (YoY) | +0.78% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 27.52% |
Owned by Institutions (%) | n/a |
Float | 6.45M |
Valuation Ratios
The trailing PE ratio is 3.62.
PE Ratio | 3.62 |
Forward PE | n/a |
PS Ratio | 1.39 |
PB Ratio | 0.59 |
P/TBV Ratio | 0.60 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | 4.66 |
EV / Sales | 1.78 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -4.78 |
Financial Position
The company has a current ratio of 0.78, with a Debt / Equity ratio of 0.22.
Current Ratio | 0.78 |
Quick Ratio | 0.43 |
Debt / Equity | 0.22 |
Debt / EBITDA | n/a |
Debt / FCF | -1.37 |
Interest Coverage | -3.71 |
Financial Efficiency
Return on equity (ROE) is -27.51% and return on invested capital (ROIC) is -4.05%.
Return on Equity (ROE) | -27.51% |
Return on Assets (ROA) | -3.22% |
Return on Capital (ROIC) | -4.05% |
Revenue Per Employee | 853.04M |
Profits Per Employee | 325.71M |
Employee Count | 14 |
Asset Turnover | 0.18 |
Inventory Turnover | 0.62 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.70% in the last 52 weeks. The beta is 0.85, so BL Pharmtech's price volatility has been lower than the market average.
Beta (5Y) | 0.85 |
52-Week Price Change | -52.70% |
50-Day Moving Average | 2,163.96 |
200-Day Moving Average | 4,206.24 |
Relative Strength Index (RSI) | 36.67 |
Average Volume (20 Days) | 300,308 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BL Pharmtech had revenue of KRW 11.94 billion and earned 4.56 billion in profits. Earnings per share was 510.56.
Revenue | 11.94B |
Gross Profit | 8.76B |
Operating Income | -3.41B |
Pretax Income | -8.18B |
Net Income | 4.56B |
EBITDA | -2.60B |
EBIT | -3.41B |
Earnings Per Share (EPS) | 510.56 |
Balance Sheet
The company has 1.64 billion in cash and 6.11 billion in debt, giving a net cash position of -4.46 billion or -501.48 per share.
Cash & Cash Equivalents | 1.64B |
Total Debt | 6.11B |
Net Cash | -4.46B |
Net Cash Per Share | -501.48 |
Equity (Book Value) | 28.09B |
Book Value Per Share | 3,124.21 |
Working Capital | -1.56B |
Cash Flow
In the last 12 months, operating cash flow was -3.19 billion and capital expenditures -1.25 billion, giving a free cash flow of -4.44 billion.
Operating Cash Flow | -3.19B |
Capital Expenditures | -1.25B |
Free Cash Flow | -4.44B |
FCF Per Share | -499.22 |
Margins
Gross margin is 73.39%, with operating and profit margins of -28.55% and 38.18%.
Gross Margin | 73.39% |
Operating Margin | -28.55% |
Pretax Margin | -68.46% |
Profit Margin | 38.18% |
EBITDA Margin | -21.74% |
EBIT Margin | -28.55% |
FCF Margin | n/a |
Dividends & Yields
BL Pharmtech does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 0.72% |
Buyback Yield | -0.78% |
Shareholder Yield | -0.78% |
Earnings Yield | 27.54% |
FCF Yield | -26.93% |
Stock Splits
The last stock split was on December 12, 2024. It was a reverse split with a ratio of 0.1.
Last Split Date | Dec 12, 2024 |
Split Type | Reverse |
Split Ratio | 0.1 |
Scores
BL Pharmtech has an Altman Z-Score of -1.55. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -1.55 |
Piotroski F-Score | n/a |